Trial Profile
A phase II study of BAY 43-9006 (NSC724772; CTEP-IND69,896) in patients with hormone refractory prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 18 Jan 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 18 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.